BG
VERV

Bellevue Group’s Verve Therapeutics VERV Stock Holding History

Bellevue Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,200
Closed -$388K – 176
2024
Q1 		$388K Sell
29,200
-9,800
-25% -$130K 0.01% 139
2023
Q4 		$544K Buy
+39,000
New +$483K 0.01% 133

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Bellevue Group's VERV Position: Q2 2024 in Review

Bellevue Group sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 29,200 shares — an estimated $388K sold.

Bellevue Group first reported a position in VERV in Q4 2023 and held it in 2 quarters. The position peaked at $544K in Q4 2023. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Bellevue Group reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bellevue Group sold 29,200 Verve Therapeutics shares in Q2 2024, an estimated $388K.
  • Bellevue Group first reported a position in Verve Therapeutics in Q4 2023 and held it in 2 quarters.
  • Bellevue Group's Verve Therapeutics position peaked at $544K in Q4 2023.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.